Graft-versus-host disease Graft-versus-host reaction
Conditions
Interventions
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: - Patients with Graft-versus-host disease - Male and female - * 18 years of age - Patient is willing and able to give written informed consent
Exclusion criteria
Exclusion criteria: - Patients taking anticoagulant medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hypothesis: Pathogenic alloreactive clones in GvHD expand in skin during rejection and may be present in blood at low levels, capable of being detected by the newly developed High-throughput TCR deep sequencing. Moreover these pathogenic clones may differ in their function during times of rejection versus tolerance. To evaluate this hypothesis, we will carry out experimentswith the following specific aims: Aim 1: to identify pathogenic T cell and ILC clones expanded in GvHD skin lesions. Aim 2: to study the function and possible pathogenicity of T cell and ILC clones identified in Aim 1. Aim 3: to track the pathogenic T cell and ILC clones identified in Aim 1 in the blood of the same GvHD patients in times of tolerance versus GvHD, and study their function and phenotypic plasticity. | — |
Countries
The Netherlands
Outcome results
None listed